Comparison of Intralesional Triamcinolone Versus Verapamil for Keloid Treatment

Launched by NISHTAR MEDICAL UNIVERSITY · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two different treatments for keloid scars, which are raised and often painful scars that can develop after an injury or surgery. The researchers want to find out whether a medication called triamcinolone, injected directly into the keloid, works better than another medication called verapamil. By comparing these two options, the study aims to help people find the most effective treatment to reduce both the appearance and discomfort of their keloids.

To participate in the trial, you need to have a keloid that is between 1 and 5 centimeters in size, located anywhere on your body, and it should have been present for less than five years. Additionally, your keloid should have a score of 5 or higher on a specific scale that measures scar characteristics. Unfortunately, pregnant or breastfeeding women, those with a family history of keloids, or certain medical conditions like acromegaly and heart disease cannot join the study. If you are eligible and decide to participate, you can expect to receive one of the treatments and will be monitored over three months to see how well it works. This research could lead to better options for managing keloids and improving the quality of life for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • size of keloid1-5 cm,
• • on any site of the body,
• • duration less then five years and
• • baseline Vancouver scar score of more the or equal to 5
• Exclusion Criteria:
• • Pregnant or lactating women,
• • family history of keloids,
• • acromegaly, and
• • congestive cardiac diseases